Promising skin cancer vaccine study pulled before it began
NCT ID NCT05799612
First seen Feb 19, 2026 · Last updated May 28, 2026 · Updated 12 times
Summary
This study aimed to find a safe dose of a custom-made mRNA vaccine for people with a rare skin cancer called cutaneous angiosarcoma. The vaccine was designed to train the immune system to fight the cancer. However, the trial was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.